‘Unintended consequences’: CSL, biotechs warn against vaccine IP waiver

The local life sciences sector will lobby against the plan to waive intellectual property rights on COVID-19 vaccines, a move its proponents hope would create more equitable access for doses around the world.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button